PSA and beyond: alternative prostate cancer biomarkers
- 1.2k Downloads
The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions.
A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected.
With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
KeywordsProstate cancer Biomarkers Prognostic Predictive Diagnostic
Compliance with ethical standards
The manuscript complies with ethical standards.
The author is supported by the National Cancer Institute at the National Institutes of Health (Grant Number RO1CA177984).
Conflict of interest
The author declares that there are no conflicts of interest.
- 3.D.N. Rodrigues, L.M. Butler, D.L. Estelles, J.S. de Bono, Molecular pathology and prostate cancer therapeutics: from biology to bedside. J. Pathol. 232, 178–184 (2013)Google Scholar
- 15.J.R. Prensner, M.A. Rubin, J.T. Wei, A.M. Chinnaiyan, Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, 127rv123 (2012)Google Scholar
- 32.W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, R.C. Flanigan, A. Patel et al., Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547 (1998)CrossRefPubMedGoogle Scholar
- 38.M. Lazzeri, A. Abrate, G. Lughezzani, G.M. Gadda, M. Freschi, F. Mistretta et al., Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 83, 606–612 (2014)CrossRefPubMedGoogle Scholar
- 39.M. Lazzeri, A. Haese, A. Abrate, A. de la Taille, J.P. Redorta, T. McNicholas et al., Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 112, 313–321 (2013)CrossRefPubMedGoogle Scholar
- 40.G. Guazzoni, L. Nava, M. Lazzeri, V. Scattoni, G. Lughezzani, C. Maccagnano et al., Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur. Urol. 60, 214–222 (2011)CrossRefPubMedGoogle Scholar
- 42.L.J. Sokoll, M.G. Sanda, Z. Feng, J. Kagan, I.A. Mizrahi, D.L. Broyles et al., A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19, 1193–1200 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP et al., Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur. Urol. (2015). doi: 10.1016/j.eururo.2015.04.039
- 55.J.N. Cornu, G. Cancel-Tassin, C. Egrot, C. Gaffory, F. Haab, O. Cussenot, Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73, 242–249 (2013)CrossRefPubMedGoogle Scholar
- 58.S.J. Freedland, L. Gerber, J. Reid, W. Welbourn, E. Tikishvili, J. Park et al., Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 86, 848–853 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 62.S. Carlsson, A. Maschino, F. Schroder, C. Bangma, E.W. Steyerberg, T. van der Kwast et al., Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol. 64, 693–699 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 65.K. Badani, D.J. Thompson, C. Buerki, E. Davicioni, J. Garrison, M. Ghadessi et al., Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 4, 600–609 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 66.E.D. Crawford, K. Ventii, N.D. Shore, New biomarkers in prostate cancer. Oncology (Williston Park) 28, 135–142 (2014)Google Scholar
- 68.M.A. Rubin, T.A. Bismar, O. Andren, L. Mucci, R. Kim, R. Shen et al., Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol. Biomarkers Prev. 14, 1424–1432 (2005)CrossRefPubMedGoogle Scholar
- 72.Bostrom PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S et al., Genomic predictors of outcome in prostate cancer. Eur. Urol. (2015). doi: 10.1016/j.eururo.2015.04.008
- 77.L.H. Broersen, G.W. van Pelt, R.A. Tollenaar, W.E. Mesker, Clinical application of circulating tumor cells in breast cancer. Cell. Oncol. 37, 9–15 (2014)Google Scholar
- 79.M.J. Kim, N.Y. Choi, E.K. Lee, M.S. Kang, Identification of novel markers that outperform EpCAM in quantifying circulating tumor cells. Cell. Oncol. 37, 235–243 (2014)Google Scholar